- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02714205
Flushing Reduction Associated With Nitrates (FRAN)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Oakland, California, United States, 94612
- University of California, San Francisco
-
San Francisco, California, United States, 94115
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women aged 40 to 62 years (consistent with the recent MSFlash hot flash network trials, and likely to maximize enrollment of highly symptomatic women)
- Postmenopausal or in the late menopausal transition. For this study, postmenopausal status will be defined by: 1) self-reported history of bilateral oophorectomy, 2) follicle stimulating hormone (FSH) levels > 20 mU/mL for those with a self-reported history of hysterectomy without bilateral oophorectomy, or 3) no self-reported history of hysterectomy or oophorectomy, but absence of menses in the past 12 months. Late menopausal transition will be defined by amenorrhea for at least 60 days in the past 12 months within the specified age group.
- Documentation of an average of 7 or more hot flashes per 24 hours as well as 4 or more moderate-to-severe hot flashes per 24 hours as recorded on a validated 7-day screening symptom diary
- Willing to refrain from initiating other treatments that are known to affect the frequency of severity hot flashes during the trial period
- Report having a current primary health care provider (such as a general practitioner, family medicine, internal medicine, or nurse practitioner providing primary care or specializing in women's health)
Exclusion Criteria:
- Current or recent use of NTG or other nitrate-containing medications (i.e., use within 1 month of screening), or intention to use nitrate-containing medication during the interventional period
- Current or recent use of medications already known to reduce the frequency or severity of hot flashes (e.g., vaginal or transdermal estrogens in the past 4 weeks; oral estrogens or progestins in the past 8 weeks; intrauterine progestin therapy in the past 8 weeks; progestin implants or estrogen alone injectable therapy in the past 3 months; estrogen pellet therapy or progestin injectable therapy in the past 6 months; clonidine, methyldopa, gabapentin, pregabalin and selective serotonin or norepinephrine reuptake inhibitors (SSRIs/SNRIs) in the past 1 month); or intention to use these medications during the interventional period
- Current or recent use of phosphodiesterase inhibitor medications (within 1 month of screening), or intention to use these medications during the interventional period
- Current or recent use of riociguat, a soluble guanylate cyclase stimulator medication, within 1 month of screening, or intention to use riociguat during the interventional period
- Self-reported history of hypertrophic obstructive cardiomyopathy, aortic valve stenosis, or mitral valve stenosis (since symptoms of these conditions may be aggravated by NTG therapy)
- Self-reported history of coronary disease (since patients with coronary disease may need NTG therapy for chest pain or may be at increased risk of new coronary events in the setting of nitrate tolerance), or evidence of prior myocardial infarction on screening electrocardiogram (ECG)
- Self-reported history of diabetes or 2 or more major risk factors for coronary disease (i.e., smoking, hypertension, or hyperlipidemia with physician-recommended pharmacologic treatment)
- Evidence of tachyarrhythmias such as atrial fibrillation or flutter without adequate rate control (>110 beats/minute) on screening ECG
- Evidence of second or third-degree atrioventricular block on screening ECG
- Hypotension based on measured resting blood pressure <90/60 at baseline; or normal resting blood pressure but evidence of orthostatic hypotension with change from supine to standing position)
- Uncontrolled hypertension based on measured resting blood pressure > 180/110 at baseline
- Self-reported headaches interfering with activities of daily activities more than twice a month, or use of prescription medication to prevent or treat headache in the past month (since these may be worsened by NTG therapy)
- Known allergy to nitroglycerin or other nitrate-based medications.
- Known skin sensitivity to adhesives (which may generalize to the NTG patches)
- Unable to complete or tolerate a brief 3-day run-in period involving the lowest available dose of NTG (0.1 mg/hr)
- Currently pregnant, gave birth within the past 3 months, planning pregnancy during the study period, or unwilling to use regular barrier contraception or abstain from sexual activity to prevent pregnancy if not yet postmenopausal
- Currently breastfeeding, breastfeeding within the past 3 months, or planning to breastfeed during the study period
- Self-report heavy alcohol use (>3 drinks in a given day or >7 drinks per week) and uncomfortable or unwilling to decrease their alcohol intake during the study period.
- Unable or unwilling to provide informed consent, fill out questionnaires, or complete study visits in English
- Report other conditions that, in the judgment of the investigators, render potential participants highly unlikely to follow the protocol, including plans to move, substance abuse, significant psychiatric problems, or severe dementia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transdermal Nitroglycerin
Daily transdermal nitroglycerin patch, starting at 0.2 mg/hr.
Dose escalation up to 0.6 mg/hr.
|
Study participants will be randomized to transdermal nitroglycerin patch or placebo patch.
Participants will wear a study medication patch daily, for 12 weeks.
|
Placebo Comparator: Placebo
Daily transdermal placebo patch.
|
Study participants will be randomized to transdermal nitroglycerin patch or placebo patch.
Participants will wear a study medication patch daily, for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline Hot Flash Frequency
Time Frame: Repeated change from baseline to 5 and 12 weeks
|
Change was calculated as the followup value minus the baseline value.
Values are model generated Least Square Means for combined 5 and 12 month time points.
|
Repeated change from baseline to 5 and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline Hot Flash Related Daily Interference Scale (HFRDIS) Score
Time Frame: Repeated change from baseline to 5 and 12 weeks
|
Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. Range 0-100, Higher score indicates lower quality of life |
Repeated change from baseline to 5 and 12 weeks
|
Change From Baseline Menopause Quality of Life (MENQOL), Vasomotor Domain Score
Time Frame: Repeated change from baseline to 5 and 12 weeks
|
Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. Range 1-8, Higher score indicates lower quality of life |
Repeated change from baseline to 5 and 12 weeks
|
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
Time Frame: Repeated change from baseline to 5 and 12 weeks
|
Change was calculated as the followup value minus the baseline value.
Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-21, Higher score indicates lower quality of life
|
Repeated change from baseline to 5 and 12 weeks
|
Change From Baseline Generalized Anxiety Disorder-7 (GAD-7) Score
Time Frame: Repeated change from baseline to 5 and 12 weeks
|
Change was calculated as the followup value minus the baseline value.
Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-21, Higher score indicates lower quality of life
|
Repeated change from baseline to 5 and 12 weeks
|
Change From Baseline Center for Epidemiologic Studies Depression (CES-D) Score
Time Frame: Repeated change from baseline to 5 and 12 weeks
|
Change was calculated as the followup value minus the baseline value.
Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-60, a higher score indicates a lower quality of life.
|
Repeated change from baseline to 5 and 12 weeks
|
Change in Baseline Frequency of Moderate-to-severe Hot Flashes
Time Frame: Repeated change from baseline to 5 and 12 weeks
|
Change was calculated as the followup value minus the baseline value.
Values are model generated Least Square Means for combined 5 and 12 month time points
|
Repeated change from baseline to 5 and 12 weeks
|
Change in Baseline Total Hot Flash Severity Score
Time Frame: Repeated change from baseline to 5 and 12 weeks
|
Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. The hot flash severity score is calculated as the sum of severity ratings for all hot flashes recorded on the symptom over a 7-day period (mild=1, moderate=2, severe=3), and then divided by 7 for the daily average score. Range 12-60, higher score indicates lower quality of life. |
Repeated change from baseline to 5 and 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Related Severe Adverse Events Defined by Common Terminology Criteria for Adverse Events (CTCAE) Severity Grade 3 or Higher.
Time Frame: Baseline to 12 weeks
|
Number of participants with treatment related severe adverse events defined by Common Terminology Criteria for Adverse Events (CTCAE) severity grade 3 or higher.
|
Baseline to 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alison Huang, MD, MPhil, MAS, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-18472
- 5R01AG050588-04 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopausal Hot Flashes
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedTreatment of Menopausal Hot FlashesUnited States
-
A. Vogel AGTerminatedMenopausal Hot FlushesSwitzerland
-
Mahidol UniversityUnknown
-
Imperial College LondonAstraZeneca; Medical Research Council; National Institute for Health Research...CompletedMenopausal FlushingUnited Kingdom
-
Hospital de Clinicas de Porto AlegreCompletedHot Flashes | Menopausal SyndromeBrazil
-
Massachusetts General HospitalNational Institutes of Health (NIH)TerminatedMenopausal DepressionUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedBreast Cancer | Hot Flashes | Menopausal SymptomsUnited States
-
Mitsubishi Tanabe Pharma America Inc.CompletedMenopause Hot FlashesUnited States
-
University of California, San FranciscoCompleted
-
University of California, San FranciscoCompleted
Clinical Trials on transdermal nitroglycerin
-
National Institute of CancerologíaUnknownLocally Advanced Non Small-Cell Lung CangerMexico
-
Cure TherapeuticsUnknown
-
Ain Shams Maternity HospitalDr. Ahmed S. Abd El-Hameed; Prof. Abdel-Megeeed I. Abdel- MegeeedCompletedInduction of Labor Affected Fetus / NewbornEgypt
-
424 General Military HospitalAristotle University Of ThessalonikiRecruitingRadial Artery SpasmGreece
-
Assiut UniversityUnknown
-
University of Texas Southwestern Medical CenterUS Department of Veterans AffairsCompletedRectal CancerUnited States
-
MediQuest TherapeuticsCompletedRaynaud's PhenomenonUnited States
-
Shiraz University of Medical SciencesCompletedManaging Preterm Labor
-
Maastricht Radiation OncologyAnticancer Fund, Belgium; Reliable Cancer TherapiesTerminatedNon Small Cell Lung Cancer (NSCLC)Netherlands
-
University of California, San FranciscoCompletedProlonged Second Stage of LaborUnited States